<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> is mostly caused by disturbances in the plasma coagulation system, <z:hpo ids='HP_0001928'>abnormalities of coagulation</z:hpo> factors are mostly risk factors for venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (VTE) </plain></SENT>
<SENT sid="1" pm="."><plain>Relatively little is known about <z:hpo ids='HP_0100724'>thrombophilias</z:hpo> that predispose to arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Although some abnormalities in the fibrinolytic pathway appear to predispose to <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, the associations are weak and often inconsistent between studies </plain></SENT>
<SENT sid="3" pm="."><plain>At present, there is not enough consistent and clinically meaningful information to include fibrinolytic parameters in a clinical <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> workup </plain></SENT>
<SENT sid="4" pm="."><plain>Controversy exists as to which patients and family members to test for <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Several testing guidelines exist </plain></SENT>
<SENT sid="6" pm="."><plain>Routine screening for inherited <z:hpo ids='HP_0100724'>thrombophilias</z:hpo> is not indicated in patients with VTE provoked by immobility, surgery, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, or in those with <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> with <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> risk factors </plain></SENT>
<SENT sid="7" pm="."><plain>Heterozygous factor V Leiden (FVL) and prothrombin 20210 mutations increase the risk for recurrent VTE only slightly once anticoagulation is stopped </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, decisions regarding the length of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy typically are not influenced by finding one of these heterozygous mutations </plain></SENT>
<SENT sid="9" pm="."><plain>The main reason to perform <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> testing in a patient is to detect a strong <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (ie, <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e>, <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome, homozygous FVL, double-heterozygous FVL plus prothrombin 20210 mutation, <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo>, and maybe <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e>) </plain></SENT>
<SENT sid="10" pm="."><plain>The finding of a strong <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> has several clinical consequences: it decreases the threshold to recommend long-term anticoagulation in a patient with unprovoked VTE; facilitates discussion regarding whether <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> or antiplatelet therapy is the preferred empiric treatment for a patient who had an unexplained arterial, nonarteriosclerotic thromboembolic event; and leads to the consideration of testing asymptomatic female family members for the identified <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>(s) so they can be counseled on their risk of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, the use of hormonal therapies, and the potential benefit of pre- and postpartum <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
</text></document>